Takeda Subsidiary Seeks $130M For Drug Firm's Spinoff Fraud
A Takeda subsidiary told the Delaware Chancery Court on Tuesday that it should get $130 million in damages from immunotherapy drug developer Harpoon Therapeutics, after a vice chancellor found that Harpoon...To view the full article, register now.
Already a subscriber? Click here to view full article